Expert Interview
A Second View: Investigating the phase 2B data on amlitelimab, an anti-OX40-ligand monoclonal antibody for the treatment of atopic dermatitis being developed by Sanofi.
Ticker(s): SNYInstitution: Carlin Dermatology
- Cosmetic and General dermatology specialist at Carlin Dermatology in San Clemente, CA.
- Treats 80 patients per month with atopic dermatitis.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
